<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004904</url>
  </required_header>
  <id_info>
    <org_study_id>NU FDA97H1</org_study_id>
    <secondary_id>NU-97H1</secondary_id>
    <secondary_id>NCI-G00-1691</secondary_id>
    <nct_id>NCT00004904</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 &quot;Veto&quot; Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were&#xD;
      destroyed by chemotherapy and radiation therapy used to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of treated donor stem cell transplantation&#xD;
      in treating patients who have hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine if megadose CD34 cells and intense immunosuppression administered&#xD;
      before and after partially matched related donor (PMRD) hematopoietic stem cell (HSC)&#xD;
      transplantation results in engraftment in patients with high risk hematologic malignancies.&#xD;
      II. Determine the incidence and severity of acute grade (I-IV) and chronic (limited or&#xD;
      extensive) graft versus host disease in patients after rigorous T-cell depletion in PMRD HSC&#xD;
      transplantation.&#xD;
&#xD;
      OUTLINE: Harvest: Bone marrow and peripheral blood stem cells (PBSC) are harvested from a&#xD;
      related 1, 2, or 3 HLA antigen mismatched donor. PBSC are selected for CD34+ cells and&#xD;
      T-cells are depleted. Conditioning: Patients undergo total body irradiation twice daily on&#xD;
      days -10 to -7 and once on day -6. Patients receive cladribine IV continuously on days -10 to&#xD;
      -6; etoposide IV over 2 hours on day -5; and cyclophosphamide IV over 2 hours, antithymocyte&#xD;
      globulin (ATG) IV over 10-12 hours, and methylprednisolone IV over 1 hour on days -4 to -2.&#xD;
      Transplantation: T-cell depleted PBSC and bone marrow are infused on day 0. Patients receive&#xD;
      G-CSF SQ daily beginning on day 0 and continuing until blood counts recover. Graft versus&#xD;
      host disease prophylaxis: Patients receive tacrolimus IV every 12 hours beginning on day -2&#xD;
      and continuing orally 4 times a day for 6-12 months at the discretion of the protocol&#xD;
      investigator. Patients receive ATG IV over 10-12 hours and methylprednisolone IV over 1 hour&#xD;
      on days 5-15 followed by a taper of methylprednisolone. Patients are followed every week&#xD;
      through day 100 and then at 6 and 12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-20 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">July 2000</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous/Nonmalignant Condition</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cladribine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven hematologic malignancy with relapse after&#xD;
        allogeneic bone marrow transplantation (BMT) or autologous BMT if no HLA matched sibling&#xD;
        donor is available OR Histologically proven acute myeloid leukemia (AML) without an&#xD;
        available HLA matched sibling donor and with one of the following: Failure of induction,&#xD;
        defined as inability to obtain remission with 2 courses of induction or failure during&#xD;
        treatment Second or greater remission OR Histologically proven acute lymphocytic leukemia&#xD;
        (ALL) in an adult over age 15 without an available HLA matched sibling donor and with one&#xD;
        of the following: Philadelphia chromosome positivity by cytogenetics or PCR Relapse or&#xD;
        second or greater remission Two or more prognostic features (over age 30, WBC on&#xD;
        presentation over 35,000/mm3, time to complete response over 4 weeks, t(4:11), or B-cell&#xD;
        ALL) OR Histologically proven chronic myelogenous leukemia In chronic phase without an A,&#xD;
        B, and DR unrelated matched donor OR In accelerated phase, defined as new cytogenetic&#xD;
        abnormalities or difficulty maintaining a normal WBC due to dose limiting cytopenias&#xD;
        (thrombocytopenias or anemia) from hydroxyurea or interferon OR In blast transformation OR&#xD;
        Histologically proven aplastic anemia without an available HLA matched sibling donor and&#xD;
        failure of an immunosuppressive therapy regimen using either cyclosporine, antithymocyte&#xD;
        globulin, or both OR Histologically proven lymphoma without an available HLA matched donor&#xD;
        and failure of at least 2 different chemotherapy regimens OR Histologically proven&#xD;
        cutaneous T-cell lymphoma without an available HLA matched donor and failure of interferon&#xD;
        and PUVA (psoralen and ultraviolet A radiation) OR Histologically proven myelodysplastic&#xD;
        syndrome without an available HLA matched sibling donor and with one of the following: 5%&#xD;
        or greater blasts in marrow Multiple cytogenetic abnormalities History of infections from&#xD;
        neutropenia 1, 2, or 3 antigen mismatched related donor available&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Physiologic age 45 and under Performance status: ECOG 0-2&#xD;
        Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic:&#xD;
        Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 2 times upper limit of&#xD;
        normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No myocardial infarction&#xD;
        within the past 6 months No coronary artery disease requiring medical therapy Resting LVEF&#xD;
        at least 40% Pulmonary: FEV1/FVC at least 60% predicted DLCO at least 60% predicted Other:&#xD;
        HIV negative No prior malignancy except basal cell or squamous cell skin cancer Other&#xD;
        malignancies for which the patient is cured by local surgical therapy, such as head and&#xD;
        neck cancer or stage I breast cancer, are considered on an individual basis Not pregnant&#xD;
        Negative pregnancy test Fertile patients must use effective contraception No psychiatric&#xD;
        illness or mental deficiency that would preclude compliance or informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See&#xD;
        Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified&#xD;
        Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K. Burt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>March 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2004</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

